Identification

Name
Linezolid
Accession Number
DB00601
Description

Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi-resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA). The drug works by inhibiting the initiation of bacterial protein synthesis.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 337.3461
Monoisotopic: 337.143784348
Chemical Formula
C16H20FN3O4
Synonyms
  • Linezolid
  • Linezolide
  • Linezolidum
  • N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
External IDs
  • INF 0026
  • PNU 100766
  • U 100
  • U 100766
  • U 766
  • U-100,766
  • U-100766

Pharmacology

Indication

For the treatment of bacterial infections caused by susceptible strains of vancomycin resistant Enterococcus faecium, Staphylococcal aureus (methicillin resistant and susceptible strains), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Linezolid is a synthetic antibacterial agent of a new class of antibiotics, the oxazolidinones, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Susceptible organisms include methicillin- and vancomycin-resistant staphylococci, vancomycin-resistant enterococci, penicillin-resistant pneumococci and anaerobes. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between linezolid and other classes of antibiotics is unlikely.

Mechanism of action

Linezolid is a synthetic antibacterial agent of the oxazolidinone class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria, certain Gram negative bacteria and anaerobic microorganisms. It selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of strains. Linezolid is also a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.

TargetActionsOrganism
A23S ribosomal RNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Linezolid is rapidly and extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%.

Volume of distribution
  • 40 to 50 L [healthy adult volunteers]
Protein binding

31%

Metabolism

Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite

Hover over products below to view reaction partners

Route of elimination
Not Available
Half-life

4.5-5.5 hours

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

Affected organisms
  • Gram negative and gram positive bacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Linezolid is combined with Abatacept.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Abciximab.
AcarboseLinezolid may increase the hypoglycemic activities of Acarbose.
AcebutololThe risk or severity of hypertension can be increased when Linezolid is combined with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Linezolid is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Linezolid is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Linezolid is combined with Acetazolamide.
AcetohexamideLinezolid may increase the hypoglycemic activities of Acetohexamide.
AcetophenazineThe risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Acetophenazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid tyramine-containing foods and supplements. Avoid food containing high amounts of tyramine (>100mg). Tyramine-containing foods include cheese, red wine, flava beans, pickled food, cured food, and alcoholic beverages.
  • Take with or without food. The absorption is unaffected by food.

Products

Product Images
International/Other Brands
Antizolid (Verisfield) / Linosept (Orion) / Linozid (Orion) / Lizbid (Abbott) / Lizemox (Molekule) / Lizolid (Glenmark) / Xolid (Corona) / Zenix (Hemofarm) / Zizolid (Biofarma) / Zodlin (FDC) / Zolinid (Teva) / Zyvoxid (Pfizer)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
LinezolidInjection, solution2 mg/1mLIntravenousHospira, Inc.2015-06-18Not applicableUS flag
LinezolidTablet600 mgOralPanda Pharmaceuticals Inc.Not applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousHospira Healthcare UlcNot applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousNeo Health Canada Inc.Not applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousTEVA Canada Limited2014-08-182018-05-17Canada flag
Linezolid InjectionSolutionIntravenousAuro Pharma IncNot applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousMda Inc.Not applicableNot applicableCanada flag
Linezolid InjectionSolutionIntravenousJamp Pharma Corporation2019-12-30Not applicableCanada flag
Linezolid InjectionSolutionIntravenousFresenius Kabi2015-06-12Not applicableCanada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-linezolidTabletOralApotex Corporation2014-08-19Not applicableCanada flag
LinezolidInjection, solution200 mg/100mLIntravenousMylan Institutional2018-07-31Not applicableUS flag
LinezolidSuspension100 mg/5mLOralGreenstone LLC2015-05-18Not applicableUS flag
LinezolidTablet600 mg/1OralAmneal Pharmaceuticals LLC2015-05-19Not applicableUS flag
LinezolidInjection, solution600 mg/300mLIntravenousSandoz Inc2016-06-15Not applicableUS flag
LinezolidInjection, solution2 mg/1mLIntravenousTeva Parenteral Medicines, Inc.2015-01-052017-09-30US flag
LinezolidInjection, solution2 mg/1mLIntravenousHospira, Inc.2015-07-072018-07-01US flag
LinezolidTablet, film coated600 mg/1OralAlembic Pharmaceuticals Limited2015-12-22Not applicableUS flag
LinezolidTablet, film coated600 mg/1OralCamber Pharmaceuticals, Inc.2015-12-21Not applicableUS flag
LinezolidInjection, solution600 mg/300mLIntravenousPiramal Critical Care Inc2019-12-18Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
J01XX08 — Linezolid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Aniline and substituted anilines / Dialkylarylamines / Fluorobenzenes / Oxazolidinones / Aryl fluorides / Acetamides / Carbamate esters / Secondary carboxylic acid amides / Organic carbonic acids and derivatives / Dialkyl ethers
show 7 more
Substituents
Acetamide / Amine / Amino acid or derivatives / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbamic acid ester
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, acetamides, morpholines, oxazolidinone (CHEBI:63607)

Chemical Identifiers

UNII
ISQ9I6J12J
CAS number
165800-03-3
InChI Key
TYZROVQLWOKYKF-ZDUSSCGKSA-N
InChI
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1
IUPAC Name
N-{[(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
SMILES
CC(=O)NC[[email protected]]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1

References

Synthesis Reference
US5688792
General References
  1. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 2006 Sep;58(3):701-4. Epub 2006 Jul 19. [PubMed:16857689]
Human Metabolome Database
HMDB0014739
KEGG Drug
D00947
KEGG Compound
C08146
PubChem Compound
441401
PubChem Substance
46504452
ChemSpider
390139
BindingDB
50116067
RxNav
190376
ChEBI
63607
ChEMBL
CHEMBL126
ZINC
ZINC000002008866
Therapeutic Targets Database
DAP000398
PharmGKB
PA450233
PDBe Ligand
ZLD
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Linezolid
AHFS Codes
  • 08:12.28.24 — Oxazolidinones
PDB Entries
3cpw / 3dll / 4k7q / 4wfa / 5nz0
FDA label
Download (106 KB)
MSDS
Download (43.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentDiabetes Mellitus1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentInfections, Gram-Positive Bacterial / Skin and Connective Tissue Diseases1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA)1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA) / Skin/Soft Tissue Infections1
4CompletedTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA)1
4CompletedTreatmentMRSA Infection1
4CompletedTreatmentVentilator-associated Bacterial Pneumonia / Ventilator-Associated Pneumonia (VAP)1
4RecruitingTreatmentIllness, Critical / Mechanical Ventilation Complication1
4TerminatedPreventionAcute acute bacterial skin and skin structure infections / Bacteremia / Endocarditis / Health Care Associated Pneumonia / Osteomyelitis/Septic Arthritis1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
Packagers
  • Fresenius Kabi AB
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Pfizer Inc.
  • Pharmacia Inc.
Dosage Forms
FormRouteStrength
InjectionIntravenous
Tablet, film coated600 mg
Tablet, coatedOral600 mg
Injection, solutionIntravenous2 mg/1mL
Injection, solutionIntravenous200 mg/100mL
Injection, solutionIntravenous600 mg/300mL
PowderNot applicable1 kg/1kg
Powder, for suspensionOral100 mg/5mL
TabletOral600 mg/1
TabletOral600 mg
Tablet, film coatedOral600 MG
SolutionParenteral2 mg/ml
Tablet, coated600 MG
Injection, solutionParenteral2 MG/ML
InjectionIntravenous2 mg/ml
Tablet, delayed releaseOral600 mg
SolutionIntravenous2 mg
SolutionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/ml
SolutionIntravenous600 mg
Tablet, film coated400 mg
SolutionIntravenous200 mg
InjectionIntravenous600 mg/300mL
Injection, solutionIntravenous400 mg/200mL
SuspensionOral100 mg/5mL
Tablet, film coatedOral
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral600 mg/1
Granule
Tablet
Powder, for suspensionOral
SolutionIntravenous
TabletOral
Injection, solution2 MG/ML
Tablet, film coatedOral400 mg
Granule, for suspensionOral100 mg/5ml
GranuleOral100 MG/5ML
Prices
Unit descriptionCostUnit
Zyvox 600 mg tablet93.81USD tablet
Zyvox 200 mg/100 ml iv soln0.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5688792No1997-11-182014-11-18US flag
CA2168560No2001-08-142014-08-16Canada flag
US6559305Yes2003-05-062021-07-29US flag
US6514529Yes2003-02-042021-09-15US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility3 mg/mLNot Available
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP0.61ALOGPS
logP0.64ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.45ChemAxon
pKa (Strongest Basic)-0.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area71.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity84.47 m3·mol-1ChemAxon
Polarizability34.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9363
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.5881
P-glycoprotein inhibitor IInhibitor0.7599
P-glycoprotein inhibitor IINon-inhibitor0.6478
Renal organic cation transporterNon-inhibitor0.7469
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5904
CYP450 1A2 substrateNon-inhibitor0.7811
CYP450 2C9 inhibitorNon-inhibitor0.8174
CYP450 2D6 inhibitorNon-inhibitor0.8112
CYP450 2C19 inhibitorNon-inhibitor0.5664
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5544
Ames testNon AMES toxic0.6839
CarcinogenicityNon-carcinogens0.8916
BiodegradationNot ready biodegradable0.9895
Rat acute toxicity2.4938 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7883
hERG inhibition (predictor II)Inhibitor0.6297
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-05a0d0b23e80851df1d5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0396000000-959c643931df034e05fc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000b-0940000000-066fc762e228726946fb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0292-0900000000-99847141a31b0134dcfa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0900000000-7cf676c358a3890ab460
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000j-0900000000-fdccf108eb9fcb8a102d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-1649000000-a1dedd5c256e9f3bfa4f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0649000000-1ac199ac8af65a2644f8

Targets

Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
In prokaryotes, the 23S rRNA is part of the large subunit (the 50S) that joins with the 30S small subunit to create the functional 70S ribosome. The ribosome is comprised of 3 RNAs: the 23S, the 16S and the 5S ribosomal RNAs. The 23S and the 5S associate with their respective proteins to make up the large subunit of the ribosome, while the 16S RNA associates with its proteins to make up the small subunit.
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sinclair A, Arnold C, Woodford N: Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci. Antimicrob Agents Chemother. 2003 Nov;47(11):3620-2. [PubMed:14576130]
  4. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS: Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9. [PubMed:15216466]
  5. Zhu W, Tenover FC, Limor J, Lonsway D, Prince D, Dunne WM Jr, Patel JB: Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):161-5. [PubMed:17393201]
  6. Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS: Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem. 2003 Jun 13;278(24):21972-9. Epub 2003 Apr 10. [PubMed:12690106]
  7. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, Legare D, Ouellette M: Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. doi: 10.1101/gr.089342.108. Epub 2009 Apr 6. [PubMed:19351617]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9. [PubMed:15482171]
  2. Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9. [PubMed:16779744]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9. [PubMed:15482171]
  2. Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9. [PubMed:16779744]

Drug created on June 13, 2005 07:24 / Updated on October 27, 2020 11:12

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates